China Shineway Pharmaceutical Group Limited (2877.HK)
HKD 9.43
(-1.26%)
HKD 9.43
(-1.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 969.51 Million CNY | 34.14% |
| 2022 | 722.77 Million CNY | 29.84% |
| 2021 | 556.67 Million CNY | 88.68% |
| 2020 | 295.03 Million CNY | -41.36% |
| 2019 | 503.15 Million CNY | -0.54% |
| 2018 | 505.87 Million CNY | 12.03% |
| 2017 | 451.55 Million CNY | -23.36% |
| 2016 | 589.19 Million CNY | -10.44% |
| 2015 | 657.9 Million CNY | -6.65% |
| 2014 | 704.77 Million CNY | 3.09% |
| 2013 | 683.64 Million CNY | 5.55% |
| 2012 | 647.7 Million CNY | -14.28% |
| 2011 | 755.6 Million CNY | -8.05% |
| 2010 | 821.75 Million CNY | 7.1% |
| 2009 | 767.3 Million CNY | 92.67% |
| 2008 | 398.24 Million CNY | -18.83% |
| 2007 | 490.64 Million CNY | 47.35% |
| 2006 | 332.97 Million CNY | -1.2% |
| 2005 | 337 Million CNY | 29.22% |
| 2004 | 260.79 Million CNY | 72.29% |
| 2003 | 151.37 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | 478.04 Million CNY | 0.0% |
| 2023 Q2 | 491.46 Million CNY | 0.0% |
| 2023 FY | 969.51 Million CNY | 34.14% |
| 2022 Q4 | 391.65 Million CNY | 0.0% |
| 2022 Q2 | 331.12 Million CNY | 0.0% |
| 2022 FY | 722.77 Million CNY | 29.84% |
| 2021 Q4 | 248.21 Million CNY | 0.0% |
| 2021 FY | 556.67 Million CNY | 88.68% |
| 2021 Q2 | 308.45 Million CNY | 0.0% |
| 2020 FY | 295.03 Million CNY | -41.36% |
| 2020 Q2 | 253.72 Million CNY | 0.0% |
| 2020 Q4 | 41.31 Million CNY | 0.0% |
| 2019 Q2 | 287.65 Million CNY | 0.0% |
| 2019 Q4 | 215.49 Million CNY | 0.0% |
| 2019 FY | 503.15 Million CNY | -0.54% |
| 2018 FY | 505.87 Million CNY | 12.03% |
| 2018 Q4 | 248.85 Million CNY | 0.0% |
| 2018 Q2 | 257.02 Million CNY | 0.0% |
| 2017 Q4 | 268.54 Million CNY | 0.0% |
| 2017 FY | 451.55 Million CNY | -23.36% |
| 2017 Q2 | 183 Million CNY | 0.0% |
| 2016 Q2 | 276.46 Million CNY | 0.0% |
| 2016 Q4 | 312.73 Million CNY | 0.0% |
| 2016 FY | 589.19 Million CNY | -10.44% |
| 2015 FY | 657.9 Million CNY | -6.65% |
| 2015 Q2 | 385.49 Million CNY | 0.0% |
| 2015 Q4 | 272.41 Million CNY | 0.0% |
| 2014 Q4 | 299.84 Million CNY | 0.0% |
| 2014 Q2 | 404.92 Million CNY | 0.0% |
| 2014 FY | 704.77 Million CNY | 3.09% |
| 2013 Q4 | 298.18 Million CNY | 0.0% |
| 2013 Q2 | 385.45 Million CNY | 0.0% |
| 2013 FY | 683.64 Million CNY | 5.55% |
| 2012 Q4 | 170.91 Million CNY | 5.56% |
| 2012 Q3 | 161.91 Million CNY | 0.0% |
| 2012 Q2 | 161.91 Million CNY | 0.0% |
| 2012 Q1 | 161.91 Million CNY | 0.0% |
| 2012 FY | 647.7 Million CNY | -14.28% |
| 2011 Q1 | 188.89 Million CNY | 0.0% |
| 2011 Q2 | 188.89 Million CNY | 0.0% |
| 2011 Q3 | 188.89 Million CNY | 0.0% |
| 2011 Q4 | 161.91 Million CNY | -14.28% |
| 2011 FY | 755.6 Million CNY | -8.05% |
| 2010 Q4 | 188.89 Million CNY | -8.05% |
| 2010 Q1 | 205.43 Million CNY | 0.0% |
| 2010 FY | 821.75 Million CNY | 7.1% |
| 2010 Q3 | 205.43 Million CNY | 0.0% |
| 2010 Q2 | 205.43 Million CNY | 0.0% |
| 2009 Q3 | 191.82 Million CNY | 0.0% |
| 2009 FY | 767.3 Million CNY | 92.67% |
| 2009 Q1 | 191.82 Million CNY | 0.0% |
| 2009 Q4 | 205.43 Million CNY | 7.1% |
| 2009 Q2 | 191.82 Million CNY | 0.0% |
| 2008 Q4 | 191.82 Million CNY | 92.67% |
| 2008 FY | 398.24 Million CNY | -18.83% |
| 2008 Q1 | 99.56 Million CNY | 0.0% |
| 2008 Q2 | 99.56 Million CNY | 0.0% |
| 2008 Q3 | 99.56 Million CNY | 0.0% |
| 2007 Q1 | 122.66 Million CNY | 0.0% |
| 2007 FY | 490.64 Million CNY | 47.35% |
| 2007 Q4 | 99.56 Million CNY | -18.83% |
| 2007 Q3 | 122.66 Million CNY | 0.0% |
| 2007 Q2 | 122.66 Million CNY | 0.0% |
| 2006 Q1 | 83.24 Million CNY | 0.0% |
| 2006 FY | 332.97 Million CNY | -1.2% |
| 2006 Q2 | 83.24 Million CNY | 0.0% |
| 2006 Q3 | 83.24 Million CNY | 0.0% |
| 2006 Q4 | 122.66 Million CNY | 47.35% |
| 2005 Q3 | 84.25 Million CNY | 0.0% |
| 2005 Q2 | 84.25 Million CNY | 0.0% |
| 2005 FY | 337 Million CNY | 29.22% |
| 2005 Q4 | 83.24 Million CNY | -1.2% |
| 2005 Q1 | 84.25 Million CNY | 0.0% |
| 2004 Q4 | 84.25 Million CNY | 24.75% |
| 2004 Q1 | 67.53 Million CNY | 0.0% |
| 2004 Q2 | 67.53 Million CNY | 0.0% |
| 2004 Q3 | 67.53 Million CNY | 0.0% |
| 2004 FY | 260.79 Million CNY | 72.29% |
| 2003 FY | 151.37 Million CNY | 0.0% |
| 2003 Q1 | 48.09 Million CNY | 0.0% |
| 2003 Q4 | 67.53 Million CNY | 40.42% |
| 2003 Q3 | 48.09 Million CNY | 0.0% |
| 2003 Q2 | 48.09 Million CNY | 0.0% |
| 2002 Q4 | 48.09 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | -823.0% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 48.43% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 694.978% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 6413.558% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 1939.503% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -5706.144% |
| Essex Bio-Technology Limited | 275.25 Million HKD | -252.217% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 3461.336% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 1013.934% |
| SSY Group Limited | 1.31 Billion HKD | 26.475% |
| JBM (Healthcare) Limited | 130.46 Million HKD | -643.13% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | -263.156% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 74.846% |